Acoustoelectric Echocardiography for Improving Prognosis & Guiding Treatment Decisions for Advanced Arrhythmias

摘要 心房纤颤（AF）的特征在于心房的无序激活，导致心脏功能受损。 功能和更严重的并发症，如栓塞性中风，心力衰竭恶化和死亡率增加。 AE影响9%的美国人口（2%的人年龄小于65岁），导致750，000例住院， 每年有13万人死亡。有一个明确的未满足的临床需要，一种新的非侵入性成像方式，能够 准确诊断、分类和定位晚期心律失常样房颤的起源， 更好的治疗决策和改善患者的预后。这项建议的目标是发展， 优化并验证首个经胸声电心脏成像（tACI）系统， 通过胸壁的心脏电流和心律失常的分辨率映射。这项专利技术结合了 具有高频射频记录的超声以远程映射身体中的电流（例如， 心脏、大脑）。如果成功，tACI将实现心室的无创电标测 在mm和ms尺度下测量心房，从而为晚期心律失常的分类提供了高诊断准确性 像房颤一样，定位其起源，指导治疗决策并减少医疗错误，从而获得更好的结果 对患者ElectroSonix的长期目标是将革命性的便携式ACI商业化并转化为 技术到诊所，医生的办公室，和护理点，以改善诊断和治疗的所有类型的 心律失常全球心脏诊断和监测设备市场预计将超过100亿美元， 2020年，复合年增长率为4.0%，而非侵入性诊断成像的特定市场（例如，ECG） 预计到2025年全球将达到10亿美元，复合年增长率为2.0%。基于tACI技术的临床系统 将通过大大提高心律失常诊断和分类的准确性来影响这一领域。此外，本发明还 通过定位心律失常的起源，所提出的临床tACI系统将有助于指导治疗决策， 减少医疗差错，提高房颤和其他晚期心律失常患者的生活质量。

ABSTRACT Atrial Fibrillation (AF) is characterized by a disorganized activation of the atrium leading to impaired cardiac function and more serious complications like embolic stroke, worsening heart failure, and increased mortality. AE affects 9% of the U.S. population (2% younger than 65) and contributes to 750,000 hospitalizations and 130,000 deaths per year. There is a clear unmet clinical need for a novel noninvasive imaging modality able to accurately diagnose, classify, and localize the origin of advanced arrythmias like AF with the goal of making better treatment decisions and improving patient outcomes. The objectives of this proposal are to develop, optimize, and validate the first transthoracic Acoustoelectric Cardiac Imaging (tACI) system for real-time, high resolution mapping of cardiac currents and arrythmias through the chest wall. This patented technology combines ultrasound with high frequency radiofrequency recording to remotely map electrical currents in the body (e.g., heart, brain) at high resolution. If successful, tACI will achieve noninvasive electrical mapping of the ventricles and atria at the mm and ms scales, thereby providing high diagnostic accuracy for classifying advanced arrythmias like AF, localizing its origins, guiding treatment decisions and reducing medical errors, leading to better outcomes for patients. The long-term goal at ElectroSonix is to commercialize and translate revolutionary and portable ACI technology to the clinic, doctor’s office, and point-of-care for improving diagnosis and treatment for all types of arrythmias. The global cardiac diagnostic and monitoring devices market is expected to surpass $10 billion by 2020, growing at 4.0% CAGR, while the specific market for noninvasive diagnostic imaging (e.g., ECG) is expected to reach $1 billion globally by 2025 at a CAGR of 2.0%. A clinical system based on tACI technology would impact this sector by greatly improving the accuracy for diagnosing and classifying arrythmias. Further, by localizing the origins of arrythmias, the proposed clinical tACI system would help guide treatment decisions, reduce medical errors, and improve quality of life for patients suffering from AF and other advanced arrythmias.